Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New peptide drug shows promise for obesity and diabetes in early trial

NCT ID NCT04838405

Disease control Sponsor: Carmot Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called CT-388 in 129 overweight or obese adults, including some with type 2 diabetes. The study aimed to check the drug's safety and how the body processes it, while also measuring weight loss and blood sugar changes. Participants received either CT-388 or a placebo by injection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CT-388 (a synthetic peptide)
What this could lead to
If successful, CT-388 could become a new treatment for obesity and type 2 diabetes, helping with weight loss and blood sugar control.
What could go wrong
This is an early Phase 1 trial focused on safety, so it is too soon to know if CT-388 works. Side effects are possible, and the results may not lead to an approved treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

129 people

The number who actually took part.

Started

Apr 2021

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males or females * 18-65 years old, inclusive * BMI 27.0-40.0, inclusive * Stable body weight for 2 months Exclusion Criteria: * Significant medical history * Uncontrolled hypertension * History of malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes

Contacts and locations

Locations

  • Carmot Clinical Research Unit 101

    Perth, Western Australia, 6009, Australia

  • Carmot Clinical Research Unit 105

    Monterrey, Nuevo León, 66260, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.